Dr. Aman is a molecular immunologist and corporate executive with over 30 years of experience in the field of immunology, microbiology, and vaccine and immunotherapeutics development for infectious diseases. Dr. Aman founded Integrated BioTherapeutics (IBT) and grew the business, now a clinical-stage company, and raised over $120M in non-dilutive funding. In 2023 Dr. Aman spun off AbVacc from IBT to focus on structure-guided design of vaccine and immunotherapeutics. He graduated from the school of Pharmacy at the University of Frankfurt in 1990. Dr. Aman later went on to complete his Ph.D. in molecular immunology at Johannes Wolfgang University in Mainz, Germany and continued his research at NIH and the University of Virginia. He then built his independent research program at the US Army Medical Research Institute of Infectious Diseases (USAMRIID) as a Principal Investigator on the development of vaccines for bacterial toxins such as staphylococcal and B. anthracis toxins as well as viral hemorrhagic fever viruses. Dr. Aman has published over 130 papers ranging from basic research in hematology, signal transduction, to vaccine and antibody discovery for infectious diseases in international scientific journals.